Literature DB >> 6090108

The mouse fibroblast growth hormone receptor: ligand processing and receptor modulation and turnover.

L J Murphy, L Lazarus.   

Abstract

The recent observation that adipose conversion of mouse 3T3 fibroblasts is stimulated by physiological concentrations of human GH (hGH) and rat GH in vitro suggested that this cell line may be suitable for the study of GH-receptor interactions. The aim of this study was to examine the binding and subsequent processing of [125I]iodo-hGH by BALB/c 3T3 mouse fibroblasts. Binding of [125I]iodo-hGH to 3T3 fibroblasts was time and temperature dependent. Apparent steady state binding was achieved after 1 and 2 h at 37 and 30 C, respectively. At 37, 30, and 20 C specifically bound [125I]iodo-hGH became increasingly resistant to removal by acid treatment (0.15 M NaCl/0.05 M glycine, pH 2.5). In contrast at 4 C or at higher temperatures in the presence of metabolic inhibitors, a greater proportion of specifically bound hGH was removed by acid treatment. Inclusion of 0.2 mM chloroquine in the incubation medium resulted in significantly more accumulation of trichloroacetic acid (TCA)-precipitable radioactivity compared to control cells without affecting the shift of radioactivity from the acid-elutable to the acid-inaccessible compartment. After removal of [125I]iodo-hGH from the medium there was a rapid loss of radioactivity (t 1/2 = 36.5 +/- 7.2 min, SE, n = 3) from the cell monolayer with a concomitant appearance in the medium of TCA-soluble radioactive species. Chloroquine reduced the rate of efflux of radioactivity from the monolayer (t 1/2 = 4.5 +/- 0.6 h, n = 3) and the appearance of TCA-soluble material in the medium. The half-time of GH receptor loss after inhibition of protein synthesis with cycloheximide (0.1 mM) was 1.25 +/- 0.14 h, n = 3). In contrast half-time of net receptor synthesis calculated from the recovery of specific [125I]iodo-hGH binding capacity after ligand-induced down-regulation was 10.2 +/- 1.5 h, n = 3). These data reveal that after binding of [125I]iodo-hGH to specific cell surface receptors there is rapid irreversible binding of GH to its receptor with a resultant reduction in receptor concentration. Degradation of [125I]iodo-hGH occurs intracellularly and involves processes which are inhibited by lysosomotropic agents. On the basis of these studies we conclude that the binding and subsequent processing of GH by 3T3 fibroblasts is qualitatively similar to that described for other polypeptide hormones and growth factors in this and other cell lines.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6090108     DOI: 10.1210/endo-115-4-1625

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

1.  Proteasome inhibitors block a late step in lysosomal transport of selected membrane but not soluble proteins.

Authors:  P van Kerkhof; C M Alves dos Santos; M Sachse; J Klumperman; G Bu; G J Strous
Journal:  Mol Biol Cell       Date:  2001-08       Impact factor: 4.138

2.  Insulin and insulin-like growth factor-I acutely inhibit surface translocation of growth hormone receptors in osteoblasts: a novel mechanism of growth hormone receptor regulation.

Authors:  K C Leung; M J Waters; I Markus; W R Baumbach; K K Ho
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

3.  Linkage of the ubiquitin-conjugating system and the endocytic pathway in ligand-induced internalization of the growth hormone receptor.

Authors:  R Govers; P van Kerkhof; A L Schwartz; G J Strous
Journal:  EMBO J       Date:  1997-08-15       Impact factor: 11.598

4.  Ubc13 and COOH terminus of Hsp70-interacting protein (CHIP) are required for growth hormone receptor endocytosis.

Authors:  Johan A Slotman; Ana C da Silva Almeida; Gerco C Hassink; Robert H A van de Ven; Peter van Kerkhof; Hendrik J Kuiken; Ger J Strous
Journal:  J Biol Chem       Date:  2012-03-20       Impact factor: 5.157

5.  βTrCP controls GH receptor degradation via two different motifs.

Authors:  Ana C da Silva Almeida; Ger J Strous; Agnes G S H van Rossum
Journal:  Mol Endocrinol       Date:  2011-10-27

6.  Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis.

Authors:  Jürgen Gent; Peter van Kerkhof; Marcel Roza; Guojun Bu; Ger J Strous
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-08       Impact factor: 11.205

Review 7.  Growth Hormone Receptor Regulation in Cancer and Chronic Diseases.

Authors:  Ger J Strous; Ana Da Silva Almeida; Joyce Putters; Julia Schantl; Magdalena Sedek; Johan A Slotman; Tobias Nespital; Gerco C Hassink; Jan A Mol
Journal:  Front Endocrinol (Lausanne)       Date:  2020-11-18       Impact factor: 5.555

8.  A novel peptide antagonist of the human growth hormone receptor.

Authors:  Reetobrata Basu; Khairun Nahar; Prateek Kulkarni; Olivia Kerekes; Maya Sattler; Zachary Hall; Sebastian Neggers; Justin M Holub; John J Kopchick
Journal:  J Biol Chem       Date:  2021-03-24       Impact factor: 5.157

9.  Small molecules to regulate the GH/IGF1 axis by inhibiting the growth hormone receptor synthesis.

Authors:  Lieke M van der Velden; Peter Maas; Miranda van Amersfoort; Elpetra P M Timmermans-Sprang; Anneloes Mensinga; Elisabeth van der Vaart; Fabrice Malergue; Henk Viëtor; Patrick W B Derksen; Judith Klumperman; Andreas van Agthoven; David A Egan; Jan A Mol; Ger J Strous
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-28       Impact factor: 6.055

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.